Patents by Inventor Zachary R. Healy

Zachary R. Healy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS
    Publication number: 20190046530
    Abstract: Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators.
    Type: Application
    Filed: October 14, 2018
    Publication date: February 14, 2019
    Inventors: KONSTANTINOS KONSTANTOPOULOS, ZACHARY R. HEALY
  • PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS
    Publication number: 20160038485
    Abstract: Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators.
    Type: Application
    Filed: September 29, 2015
    Publication date: February 11, 2016
    Inventors: Konstantinos Konstantopoulos, Paul Talalay, Zachary R. Healy
  • PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS
    Publication number: 20100015085
    Abstract: Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators.
    Type: Application
    Filed: April 30, 2007
    Publication date: January 21, 2010
    Inventors: Konstantinos Konstantopoulos, Paul Talalay, Zachary R. Healy